# Imcyse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imcyse

- Industry: Pharmaceuticals
- Headquarters: Belgium
- Website: www.imcyse.com
- Total disclosed funding: $59M
- Latest round: Series B (Mar 30, 2021)
- Investors on record: 8

## About

Based in Liege, Belgium, and founded in 2011, Imcyse SA provides therapies for severe, chronic autoimmune diseases. In June 2019, Imcyse SA raised EUR 28 million in series B funding led by EQT Life Sciences, with participation from Epimède, SFPI-FPIM, etc. In February 2021, the firm raised EUR 21.3 million in Series B funding led by investor Pfizer, Inc., with participation from returning investors Biogenosis, Epimède, K.U. Leuven Research & Development, Noshaq, SFPI-FPIM, and Société Régionale d'Investissement de Wallonie. As of 2024, Denis Bedoret is the Chief Executive Officer (CEO) of the company. 

Imcyse SA provides the Imotope platform, designed to prevent, halt, and potentially cure autoimmune diseases. The company's platform generates cytolytic T cells that specifically target and eliminate abnormal disease pathways without adversely affecting the overall immune system. Imotopes is a small and irregular peptide injections, that prompt an immune response and obstruct autoimmune pathways.

## Funding rounds

- Series B, Mar 30, 2021, $25M — K.U. Leuven Research & Development, Société Régionale d'Investissement de Wallonie, Pfizer Inc., SFPI-FPIM, Noshaq, Epimede, Biogenosis
- Series B, Sep 12, 2018, $33M — K.U. Leuven Research & Development, EQT Life Sciences, Société Régionale d'Investissement de Wallonie, SFPI-FPIM, Noshaq, Epimede, Biogenosis

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Société Régionale d'Investissement de Wallonie — Series B
- SFPI-FPIM — Series B
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series B
- Epimede (https://capitalatlas.ai/funds/epimede) — Series B
- Biogenosis — Series B
- Pfizer Inc. — Series B